2023
Clinical trial design for non-muscle-invasive bladder cancer
Tan W, Hall E, Kamat A, Kelly J. Clinical trial design for non-muscle-invasive bladder cancer. Nature Reviews Urology 2023, 20: 575-576. PMID: 37328547, DOI: 10.1038/s41585-023-00789-0.Peer-Reviewed Original Research
2021
Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era?
Tan W, Wong A, Mahmalji W, Raza A. Is there still a role for digital rectal examination in the prostate cancer diagnostic pathway in the COVID-19 and post COVID-19 era? The Aging Male 2021, 24: 92-94. PMID: 34319201, DOI: 10.1080/13685538.2020.1786047.Peer-Reviewed Original ResearchConceptsDigital rectal examinationProstate cancer diagnostic pathwayProstate specific antigenSuspicion of prostate cancerCancer diagnostic pathwayDiagnostic pathwayProstate cancerRectal examinationClinical suspicion of prostate cancerAbnormal digital rectal examinationProstate specific antigen measurementsRaised prostate specific antigenReferral to secondary careClinical suspicionSpecific antigenClinical examinationClinical assessmentCOVID-19 eraCancerMRISecondary careCOVID-19ExaminationRadiology servicesCoronavirus-19
2018
The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review
Khetrapal P, Lee M, Tan W, Dong L, de Winter P, Feber A, Kelly J. The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 66: 56-63. PMID: 29684744, DOI: 10.1016/j.ctrv.2018.03.007.Peer-Reviewed Original ResearchConceptsCirculating tumor cellsBladder cancerBlood-based biomarkersValidation cohortTumor cellsDiagnostic value of circulating tumor cellsCirculating tumor cell biomarkerDetection of bladder cancerSystematic reviewCell-free DNAIndependent validation cohortCirculating nucleic acidsSolid cancersAUC/ROC valueUrinary biomarkersMedian numberDiagnostic valueCancerBiomarker sensitivityBiomarkersNucleic acidsBladderSystematic searchCohortAUC/ROCWho Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients
Tan W, Feber A, Sarpong R, Khetrapal P, Rodney S, Jalil R, Mostafid H, Cresswell J, Hicks J, Rane A, Henderson A, Watson D, Cherian J, Williams N, Brew-Graves C, Kelly J, collaborators O. Who Should Be Investigated for Haematuria? Results of a Contemporary Prospective Observational Study of 3556 Patients. European Urology 2018, 74: 10-14. PMID: 29653885, DOI: 10.1016/j.eururo.2018.03.008.Peer-Reviewed Original ResearchConceptsUrinary tract cancerIncidence of urinary tract cancerInvestigation of haematuriaRisk of urinary tract cancerClinically significant cancerDiagnosis of urinary tract cancerHigh-risk cancerProspective observational studyIncidence of cancerSignificant cancerAge thresholdBladder cancerSmoking historyVisible bloodOlder patientsHaematuriaMale genderConsensus recommendationsPatientsObservational studyCancerPatient preferencesCancer diagnosisLack of consensusAgeUrinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet?
Tan W, Tan W. Urinary biomarker for the detection of recurrence following non- muscle invasive bladder cancer: are we there yet? Translational Andrology And Urology 2018, 7: s109-s110. PMID: 29644175, PMCID: PMC5881187, DOI: 10.21037/tau.2017.12.18.Peer-Reviewed Original Research
2017
UroMark—a urinary biomarker assay for the detection of bladder cancer
Feber A, Dhami P, Dong L, de Winter P, Tan W, Martínez-Fernández M, Paul D, Hynes-Allen A, Rezaee S, Gurung P, Rodney S, Mehmood A, Villacampa F, de la Rosa F, Jameson C, Cheng K, Zeegers M, Bryan R, James N, Paramio J, Freeman A, Beck S, Kelly J. UroMark—a urinary biomarker assay for the detection of bladder cancer. Clinical Epigenetics 2017, 9: 8. PMID: 28163793, PMCID: PMC5282868, DOI: 10.1186/s13148-016-0303-5.Peer-Reviewed Original ResearchConceptsDetection of bladder cancerEpigenetic alterationsSequencing assayNovel high-throughputBladder cancerBackgroundBladder cancerNext-generation sequencing assayUrinary biomarkersDNA methylationMuscle-invasive bladder cancerUrinary biomarker assaysSediment DNAAnalysis pipelineVoided urine samplesDetection of BCPrimary BCHigh-throughputCystoscopic examinationVoided urineDNAIndependent cohortAssayBiomarker panelDiagnosed BCCancer
2016
Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia
Tan W, Rodney S, Lamb B, Feneley M, Kelly J. Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia. Cancer Treatment Reviews 2016, 47: 22-31. PMID: 27231966, DOI: 10.1016/j.ctrv.2016.05.002.Peer-Reviewed Original ResearchConceptsNon-muscle invasive bladder cancerBladder cancerAnalysis of guidelinesBladder cancer casesUnited StatesCancer casesInvasive bladder cancerIntravesical treatmentTransurethral resectionExpensive cancerTreatment modalitiesSurveillance protocolsContemporary guidelinesUnited KingdomGuidelinesIntensive treatmentBladderCancerInternational ConsultationTreatmentConsultationUnits
2014
Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer
Gurung P, Veerakumarasivam A, Williamson M, Counsell N, Douglas J, Tan W, Feber A, Crabb S, Short S, Freeman A, Powles T, Hoskin P, West C, Kelly J. Loss of expression of the tumour suppressor gene AIMP3 predicts survival following radiotherapy in muscle‐invasive bladder cancer. International Journal Of Cancer 2014, 136: 709-720. PMID: 24917520, DOI: 10.1002/ijc.29022.Peer-Reviewed Original ResearchConceptsMuscle-invasive bladder cancerMuscle-invasive bladder cancer patientsTissue-microarrayBladder cancerAssociated with survivalPredictive of survivalMethylation-specific PCRColony forming assayLoss of expressionRadical cystectomyRadiotherapy trialsRadiosensitising effectPrognostic valueMechanism of gene silencingRadiotherapyResponse to ionising radiationClinical biomarkersPatientsProtein expressionCancerMeta-analysisDNA damage responseCystectomySurvivalBladder
2011
Biochemical Recurrence after Radical Radiotherapy for Localised Prostate Cancer — the Cardiff Experience
Tan W. Biochemical Recurrence after Radical Radiotherapy for Localised Prostate Cancer — the Cardiff Experience. Clinical Oncology 2011, 23: s55. DOI: 10.1016/j.clon.2011.01.489.Peer-Reviewed Original Research